4 respiratory therapies get PBAC recommendations

Drugs for asthma, pulmonary artery hypertension and non-small cell lung cancer have received recommendations for PBS listing from the Pharmaceutical Benefits Advisory Committee (PBAC). At its July 2020 meeting, the PBAC recommended the following listings: Atectura Breezhaler: listing of the fixed dose combination (FDC) of mometasone furoate with indacaterol for the maintenance treatment of asthma. ...

Already a member?

Login to keep reading.

© 2021 the limbic